Biologics for the Treatment of Juvenile Idiopathic Arthritis

Author(s): Dimitri Poddighe*, Micol Romano, Maurizio Gattinara, Valeria Gerloni

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 42 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Juvenile Idiopathic Arthritis (JIA) is one of the most common chronic diseases in children. Recently, the management of JIA has substantially changed, thanks to the availability of new treatment options, represented by biological drugs or biologics. These drugs modulate the specific mechanisms of the immune systems, such as TNF-α, IL-1 and IL-6 signaling, or lymphocyte activation and/or functioning. In this review, we provide a comprehensive discussion on the current recommendations and clinical evidence regarding the use of the available biologics in the treatment of JIA; moreover, the main pharmacokinetic and pharmacodynamic aspects of any specific biologic drug have been summarized.

Keywords: Biologics, JIA, clinical evidence, immunology, pharmacodynamics, pharmacokinetics.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 21 May, 2018
Page: [5860 - 5893]
Pages: 34
DOI: 10.2174/0929867325666180522085716
Price: $65

Article Metrics

PDF: 59
HTML: 14
PRC: 1